BPTH · Bio-Path Holdings, Inc.
$0.13
-0.08 (-38.10%)
At close · Feb 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 20, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company’s available cash and cash equivalents of $0.1 million at March 31, 2026 will not be sufficient to fund liquidity and capital expenditure requirements for the next 12 months from the date of issuance of these consolidated financial statements. Therefore, substantial doubt exists about the Company’s ability to continue as a going concern.”View the 10-Q filed May 20, 2026
Market Cap
$1.51M
Shares
50.30M
Volume · Feb 19
1.56M
Avg daily vol (3M)
2.45M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.13
Open$0.20
Day$0.12–0.21
52W close$0.13–8.80
Avg vol 30d710K
Short int5K · 0.0% float · 1.0d
Short vol12%
Last earningsNov 15, 2024
DataJan 2020–Feb 2025
Filing10-Q · May 20
Up next
filed May 20, 2026
call held Nov 15, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$37,000
Trailing 12 months
Net income (TTM)
−$11.18M
Trailing 12 months
Revenue growth YoY
+184.6%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+32.3%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−90%
below
Price vs 50-day avg
−85%
below
RSI (14)
17
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−85%
trailing
6-month return
−89%
trailing
YTD return
−89%
this year
Relative strength
−98%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-91% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.01% of float · ▲ +189.3% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
2 holders — near 3-yr low, contrarian setup
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+88%
Y/Y
Free cash flow
$-10.6M
Balance sheet
$1.2M
net cash
Quant / Vol
risk profile
Volatility
192%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
91.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−90%
Bearish
Price vs 50-day avg
−85%
Bearish
RSI (14)
17
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-91% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.01% of float · ▲ +189.3% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
2 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $9
vs 200-day avg -90%
vs 50-day avg -85%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BPTH
this stock
Bio-Path Holdings, Inc.
|
$1.51M | — | -100.0% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
2
- % held
- 0.1%
- Net QoQ
- -287.9K sh
- Top holder
- XTX Topco Ltd
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BPTH | -83.1% | -84.5% | -89.0% | -84.0% | -88.8% |
| SPY | +1.3% | +1.6% | +9.3% | +1.9% | +4.6% |
| vs SPY | -84.4% | -86.2% | -98.3% | -85.8% | -93.4% |